| Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens P Larsson, H Engqvist, J Biermann, E Werner Rönnerman, ... Scientific reports 10 (1), 5798, 2020 | 154 | 2020 |
| Pan-cancer analysis identifies BIRC5 as a prognostic biomarker A Fäldt Beding, P Larsson, K Helou, Z Einbeigi, TZ Parris BMC cancer 22 (1), 322, 2022 | 36 | 2022 |
| Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes H Engqvist, TZ Parris, J Biermann, EW Rönnerman, P Larsson, ... Scientific reports 10 (1), 7946, 2020 | 17 | 2020 |
| Pan-cancer analysis of genomic and transcriptomic data reveals the prognostic relevance of human proteasome genes in different cancer types P Larsson, D Pettersson, H Engqvist, E Werner Rönnerman, ... BMC cancer 22 (1), 993, 2022 | 3 | 2022 |
| Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro M Olsson, P Larsson, J Johansson, VR Sah, TZ Parris Frontiers in Cell and Developmental Biology 11, 2023 | 1 | 2023 |
| Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer P Larsson, D Pettersson, M Olsson, S Sarathchandra, A Abramsson, ... Cell Death Discovery 10 (1), 57, 2024 | | 2024 |
| Optimization of Cell Viability Assays for Drug Sensitivity Screens P Larsson, TZ Parris Cell Viability Assays: Methods and Protocols, 287-302, 2023 | | 2023 |
| Abstract P2-06-19: The effect of UBE2C expression on intrinsic chemosensitivity in breast cancer cell lines TZ Parris, P Larsson, J Biermann, H Engqvist, E Werner-Rönnerman, ... Cancer Research 79 (4_Supplement), P2-06-19-P2-06-19, 2019 | | 2019 |
Toshima Z. ParrisAssociate Professor, University of GothenburgVerified email at oncology.gu.se
